Agnostic dMMR tumour PD-1 inhibitor approach may avoid resection
Patients with deficient mismatch repair (dMMR) cancers may not require surgery after 6 months of neoadjuvant treatment with the PD-1 inhibitor dostarlimab, suggests research published in The New England Journal of Medicine.
